EGFR ligands secreted by tumor infiltrating myeloid cells stimulated EGFR/MAPK signaling and increased the expression of PD-L1 on the epithelial cells to activate the PD-1/PD-L1 checkpoint (49). The gene discussed is EGFR; the disease is neoplasm.